Biohaven Ltd. (New York Stock Exchange:BHVN)
| Market Cap | 2.22B-9.9% |
| Revenue (ttm) | 0 |
| Net Income | -586.84M+23.5% |
| EPS | -4.64+39.4% |
| Shares Out | 151.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,491,335 |
| Open | 16.10 |
| Previous Close | 11.75 |
| Day's Range | 14.45 - 16.54 |
| 52-Week Range | 7.48 - 18.57 |
| Beta | 3.20 |
| Analysts | Buy |
| Price Target | 24.67(+67.94%) |
| Earnings Date | Nov 9, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About BHVN
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
$BHVN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in BHVN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BHVN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BHVN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BHVN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BHVN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BHVN
| ETF | Est. Holding Size |
|---|---|
| XBIState Street SPDR S&P Biotech ETF | $45.44M |
| IWMiShares Russell 2000 ETF | $39.23M |
| VXFVanguard Extended Market ETF | $18.72M |
| IWOiShares Russell 2000 Growth ETF | $14.56M |
| IBBiShares Biotechnology ETF | $11.61M |
| VTWOVanguard Russell 2000 ETF | $10.35M |
Estimated from each fund’s disclosed top holdings × AUM
BHVN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BHVN’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.